Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma.

[1]  J. Braun,et al.  Plasma RNA quantification and HIV-1 divergent strains. , 2003, Journal of acquired immune deficiency syndromes.

[2]  V. Soriano,et al.  Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma , 2002, Journal of Clinical Microbiology.

[3]  G. Leckie,et al.  A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma. , 2001, Journal of virological methods.

[4]  V. Soriano,et al.  Comparative Performance of Three Viral Load Assays on Human Immunodeficiency Virus Type 1 (HIV-1) Isolates Representing Group M (Subtypes A to G) and Group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR Version 1.5, and Quantiplex HIV-1 RNA Version 3.0 , 2001, Journal of Clinical Microbiology.

[5]  D. Paraskevis,et al.  Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. , 2001, Journal of virological methods.

[6]  L. Drago,et al.  Evaluation of the Abbott LCx HIV-1 RNA Quantitative, a New Assay for Quantitative Determination of Human Immunodeficiency Virus Type 1 RNA , 2000, Journal of Clinical Microbiology.

[7]  G. Schochetman,et al.  Quantification of HIV-1 group M (subtypes A-G) and group O by the LCx HIV RNA quantitative assay. , 2000, Journal of virological methods.

[8]  J. Gallant,et al.  Strategies for long-term success in the treatment of HIV infection. , 2000, JAMA.

[9]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[10]  R. Dewar,et al.  Comparison of the Quantiplex Version 3.0 Assay and a Sensitized Amplicor Monitor Assay for Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma Samples , 1999, Journal of Clinical Microbiology.

[11]  M. Fischl.  Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. , 1999, AIDS.

[12]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[13]  M. Peeters,et al.  Comparison of the QUANTIPLEX HIV-1 RNA 2.0 Assay with the AMPLICOR HIV-1 MONITOR 1.0 Assay for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma of Patients Receiving Stavudine-Didanosine Combination Therapy , 1998, Journal of Clinical Microbiology.

[14]  D. Brambilla,et al.  Ultrasensitive Reverse Transcription-PCR Assay for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[15]  Julio S. G. Montaner,et al.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.

[16]  W. S. Clark,et al.  Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[17]  L. Pedneault,et al.  Intra-Assay Performance Characteristics of Five Assays for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[18]  H. Salomón,et al.  HIV-1 viral load: comparative evaluation of three commercially available assays in Argentina. , 1998, Acta physiologica, pharmacologica et therapeutica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y [de] la Asociacion Latinoamericana de Farmacologia.

[19]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, Journal of Infectious Diseases.

[20]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[21]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[22]  J Kolberg,et al.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. , 1997, Nucleic acids research.

[23]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[24]  D. R. Kuritzkes,et al.  HIV viral load markers in clinical practice , 1996, Nature Medicine.

[25]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.